| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CIRCIO Aktie jetzt für 0€ handeln | |||||
| Do | Circio Holding ASA: Corr: Atlas Holdings for CIRCIO | 1 | Oslo Børs | ||
| Do | Circio Holding ASA: Atlas Holdings for CIRCIO | 1 | Oslo Børs | ||
| 20.10. | Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds | 1 | Oslo Børs | ||
| 15.10. | Circio Holding ASA: Requested Conversion of Convertible Bonds | 2 | Oslo Børs | ||
| 08.10. | Circio Holding ASA: Circio presents comprehensive circVec in vivo data package demonstrating 40-fold improvement over conventional AAV gene delivery at ESGCT 2025 | 3 | Oslo Børs | ||
| 06.10. | Circio Holding ASA: Requested Conversion of Convertible Bonds | 4 | Oslo Børs | ||
| 01.10. | Circio Holding ASA Approval and publication of prospectus for potential future share issues and conversion of convertible bonds | 3 | Oslo Børs | ||
| 01.10. | Circio Holding ASA: Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025 | 9 | Oslo Børs | ||
| 09.09. | Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds | 2 | Oslo Børs | ||
| 05.09. | Circio Holding ASA - Conversion of Convertible Bonds and funding requested under Additional Financing Commitment from Atlas | 1 | Oslo Børs | ||
| 28.08. | Circio 1H 2025 presentation: circVec technology shows 10-40x advantage in gene therapy | 3 | Investing.com | ||
| 04.08. | Circio Holding ASA Funding requested under additional financing commitment from Atlas | 1 | Oslo Børs | ||
| 07.07. | Circio Expands Laboratory Operations in Stockholm, Sweden | 8 | Contract Pharma | ||
| 04.07. | Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds | 2 | Oslo Børs | ||
| 30.06. | Circio, NeoRegen Biotech to Advance Circular RNA Delivery Collaboration | 3 | Contract Pharma | ||
| 30.06. | Circio Holding ASA: NeoRegen Biotech and Circio advance circular RNA delivery collaboration into in vivo stage | 8 | Oslo Børs | ||
| 20.06. | Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds | 4 | Oslo Børs | ||
| 17.06. | Circio Holding ASA - Funding requested under financing commitment from Atlas | 1 | Oslo Børs | ||
| 17.06. | Circio Holding ASA: Requested Conversion of Convertible Bonds | 1 | Oslo Børs | ||
| 16.06. | Circio Holding ASA: TG01 mutant RAS cancer vaccine data showing clinical benefit in multiple myeloma presented at EHA 2025 | 1 | Oslo Børs | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,096 | -0,76 % | BB Biotech & Evotec: Biotech immer noch historisch "billig"? Und die bessere Aktie ist? | BB Biotech & Evotec: Zwei Aktien, die ein klar unterschiedliches Risikopotential bieten. Deshalb die Frage: Wird höheres Risiko durch höhere Gewinnchncen ausgeglichen? Ein Aktienvergleich für Anleger... ► Artikel lesen | |
| MEDIGENE | 0,050 | -12,54 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| VALNEVA | 3,978 | +0,20 % | Valneva-Aktie überrascht die Börse - was jetzt hinter den Bewegungen steckt!! | ||
| NOVAVAX | 7,261 | -0,67 % | Novavax stock price target raised to $11 from $10 at H.C. Wainwright | ||
| INOVIO PHARMACEUTICALS | 2,060 | -0,96 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 1,148 | -1,37 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| BAVARIAN NORDIC | 32,000 | -0,12 % | Bavarian Nordic A/S: Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines | COPENHAGEN, Denmark, October 28, 2025 - Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa.
			The donation of... ► Artikel lesen | |
| VAXART | 0,260 | -0,84 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,420 | -4,70 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 10,915 | -1,18 % | Emergent BioSolutions Reports Third Quarter 2025 Financial Results | Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,990 | -1,38 % | TELIX PHARMACEUTICALS LIMITED: Pending Release of Shares from Voluntary Escrow | ||
| SINOVAC BIOTECH | - | - | Sinovac appoints UHY as auditor in bid to resume NASDAQ trading | ||
| CYTOMX THERAPEUTICS | 2,868 | -0,76 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| AGENUS | 3,240 | -0,61 % | Agenus Inc.: Frankreich gewährt erstattungsfähigen Compassionate-Use-Zugang (AAC) zu BOT/BAL von Agenus bei refraktärem MSS-metastasiertem kolorektalem Karzinom | Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen im Bereich der Immunonkologie, gab heute bekannt, dass seine in der Erprobung befindliche Kombinationstherapie aus Botensilimab und Balstilimab... ► Artikel lesen | |
| NORTHWEST BIOTHERAPEUTICS | 0,200 | -0,99 % | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed | BETHESDA, Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune... ► Artikel lesen |